therapy involves the programming or activation of specialized
cells (T-cells) in the immune system that are capable of killing
cancer cells. Depending on the type of T-cell therapy, the cells
can be acquired from the patient or a donor. When acquired
from donors, it is called adoptive immunotherapy.
T-cell therapy has been described as a "living drug" - combining
the specificity of antibodies (targeting a molecule on the tumor
such as cd10) with the killing power of t-cells.
Efficacy of this approach is dependent on the ability of the
enhanced cells to expand and persist in the body after being
given to the patient by vein. The safety of this treatment
can be a concern as this approach can lead to serious